Techpoint, Inc. (THPTF) Stock Analysis
DELISTED 2026
What happened to Techpoint, Inc. (THPTF) stock?
Techpoint, Inc. (THPTF) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Techpoint, Inc. (THPTF) trades at $19.75. Therapeutic Products Inc. , trading as Theratechnologies, is a biopharmaceutical company focused on the development and commercialization of innovative therapies. Market cap: $363M, Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for THPTF: THPTF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates THPTF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
THPTF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Techpoint, Inc. (THPTF) Healthcare & Pipeline Overview
Theratechnologies is a biopharmaceutical company specializing in metabolic disorders and infectious diseases, primarily HIV. Its key product, EGRIFTA SV, targets HIV-associated lipodystrophy. The company focuses on niche markets with unmet needs, differentiating itself through specialized therapies and strategic partnerships within the biopharmaceutical landscape.
What Is the Investment Thesis for THPTF?
Theratechnologies presents a focused investment opportunity within the biopharmaceutical sector, driven by its specialization in HIV-related metabolic disorders and a growing pipeline. The company's primary value driver is EGRIFTA SV, which addresses a significant unmet need in HIV-associated lipodystrophy. Growth catalysts include expanding market penetration for EGRIFTA SV, potential label expansions, and advancement of its pipeline programs. Key metrics to monitor include revenue growth from EGRIFTA SV sales, R&D expenditure efficiency, and progress in clinical trials. Potential risks include competition from alternative therapies, regulatory hurdles, and reliance on a limited product portfolio. The company's strategic focus on niche markets and commitment to innovation position it for sustained growth within the biopharmaceutical landscape.
Based on FMP financials and quantitative analysis
THPTF Key Highlights
EGRIFTA SV is a growth hormone-releasing factor (GRF) analog indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy.
- Theratechnologies focuses on addressing unmet medical needs in metabolic disorders and infectious diseases.
- The company has a strategic presence in North America, particularly in the United States and Canada.
- Theratechnologies differentiates itself through specialized therapies and strategic partnerships.
- The company is actively involved in research and development efforts to expand its product pipeline.
Who Are THPTF's Competitors?
THPTF is benchmarked below against 7 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GILD Gilead Sciences, Inc. | $143.44 | -2.82% | $178B | 62 |
| VTRS Viatris Inc. | $16.25 | +0.46% | $18.9B | 31 |
| MRK Merck & Co., Inc. | $152.22 | +12.61% | $376B | 75 |
| ASRPF Asarina Pharma AB (publ) | $2.45 | +0.00% | $41.8M | 43 |
| DMTX Dimension Therapeutics, Inc. | $5.95 | -0.42% | 60 | |
| ARIA ARIAD Pharmaceuticals, Inc. | $25.09 | +0.00% | 57 | |
| SAII Software Acquisition Group Inc. II | $8.98 | -5.97% | 44 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are THPTF's Key Strengths?
Specialized expertise in HIV-associated metabolic disorders.
- Proprietary product: EGRIFTA SV.
- Established market presence in North America.
- Strong relationships with healthcare providers.
What Are THPTF's Weaknesses?
Reliance on a limited product portfolio.
- High dependence on EGRIFTA SV sales.
- Limited geographic diversification.
- Small market capitalization.
What Could Drive THPTF Stock Higher?
Clinical trial results for pipeline programs.
- Expansion of EGRIFTA SV market penetration.
- Potential label expansion for EGRIFTA SV.
- Strategic partnerships and collaborations.
What Are the Key Risks for THPTF?
Rich valuation — a P/E of 42.6 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.
- Competition from alternative therapies.
- Regulatory hurdles and pricing pressures.
- Patent expiration for EGRIFTA SV.
- Economic downturns affecting healthcare spending.
What Are the Growth Opportunities for THPTF?
- Expanding Market Penetration of EGRIFTA SV: Theratechnologies has the opportunity to increase the market penetration of EGRIFTA SV within the existing patient population of HIV-infected individuals with lipodystrophy. This can be achieved through targeted marketing campaigns, increased awareness among healthcare providers, and improved patient access programs. The market size for HIV-associated lipodystrophy treatments is estimated to grow as the HIV-positive population ages and the prevalence of metabolic complications increases. Timeline: Ongoing.
- Potential Label Expansion for EGRIFTA SV: Theratechnologies can pursue label expansion for EGRIFTA SV to include additional indications or patient populations. This could involve conducting clinical trials to evaluate the efficacy and safety of EGRIFTA SV in other metabolic disorders or HIV-related complications. Successful label expansion would significantly broaden the addressable market for EGRIFTA SV and drive revenue growth. Timeline: 2-3 years.
- Advancement of Pipeline Programs: Theratechnologies is actively involved in research and development efforts to expand its product pipeline. The company can focus on advancing its preclinical and clinical programs through key milestones, such as IND filings, initiation of clinical trials, and publication of clinical data. Successful development and commercialization of new products would diversify the company's revenue streams and reduce reliance on EGRIFTA SV. Timeline: 3-5 years.
- Strategic Partnerships and Collaborations: Theratechnologies can pursue strategic partnerships and collaborations with other pharmaceutical companies, research institutions, or healthcare organizations. These partnerships can provide access to new technologies, expertise, or funding, accelerating the development and commercialization of innovative therapies. Collaborations can also expand the company's geographic reach and market access. Timeline: Ongoing.
- Geographic Expansion: Theratechnologies can expand its geographic presence beyond North America to include other regions with significant unmet medical needs in metabolic disorders and infectious diseases. This could involve establishing distribution agreements, licensing arrangements, or direct commercial operations in key markets. Geographic expansion would increase the company's revenue potential and diversify its customer base. Timeline: 3-5 years.
What Are THPTF's Competitive Advantages?
- Proprietary product: EGRIFTA SV is a unique therapy for HIV-associated lipodystrophy.
- Specialized expertise: Focus on metabolic disorders and infectious diseases.
- Established market presence: Strong relationships with healthcare providers in North America.
- Regulatory exclusivity: Potential for patent protection and market exclusivity for EGRIFTA SV.
What Does THPTF Do?
Theratechnologies, operating as Theratechnologies Inc. (THPTF), is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies. Established with a focus on addressing unmet medical needs, the company has strategically positioned itself in the areas of metabolic disorders and infectious diseases, particularly HIV. Theratechnologies' primary product is EGRIFTA SV (tesamorelin for injection), a growth hormone-releasing factor (GRF) analog indicated to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. This condition, characterized by abnormal fat distribution, affects a significant portion of individuals undergoing antiretroviral therapy. Beyond EGRIFTA SV, Theratechnologies is actively involved in research and development efforts aimed at expanding its product pipeline. The company's geographic reach extends across North America, with a strong presence in the United States and Canada. Theratechnologies differentiates itself through a combination of specialized therapies, strategic partnerships, and a commitment to addressing niche markets with limited treatment options. The company's evolution has been marked by a focus on scientific innovation and a dedication to improving the quality of life for patients with challenging medical conditions.
What Products and Services Does THPTF Offer?
- Develop and commercialize innovative therapies for unmet medical needs.
- Focus on metabolic disorders and infectious diseases, particularly HIV.
- Market EGRIFTA SV (tesamorelin for injection) for HIV-associated lipodystrophy.
- Conduct research and development to expand their product pipeline.
- Address the needs of patients with challenging medical conditions.
- Operate primarily in North America, with a presence in the United States and Canada.
How Does THPTF Make Money?
- Develop and commercialize proprietary pharmaceutical products.
- Generate revenue through sales of EGRIFTA SV.
- Invest in research and development to create new therapies.
- Establish partnerships for product distribution and market access.
What Industry Does THPTF Operate In?
The biopharmaceutical industry is characterized by intense competition, high research and development costs, and stringent regulatory requirements. Companies like Theratechnologies operate in a landscape driven by innovation and the pursuit of novel therapies. The market for HIV-related treatments is mature but still presents opportunities for specialized therapies that address specific complications, such as lipodystrophy. The industry is also witnessing a growing emphasis on personalized medicine and targeted therapies, aligning with Theratechnologies' focus on niche markets and unmet medical needs. Overall, the biopharmaceutical sector is expected to continue growing, driven by aging populations, increasing healthcare expenditure, and advancements in biotechnology.
Who Are THPTF's Key Customers?
- HIV-infected patients with lipodystrophy.
- Healthcare providers who treat HIV-related complications.
- Pharmacies and distributors that supply EGRIFTA SV.
- Hospitals and clinics that offer HIV care.
Company Profile
Techpoint, Inc. operates in the Semiconductors industry within the Technology sector. It is headquartered in San Jose, US. The company is led by CEO Fumihiro Kozato. THPTF has traded publicly since 2021.
How Techpoint, Inc. Is Valued
Techpoint, Inc. carries a market capitalization of $363M, placing it in the small-cap category.
Key Financial Metrics
Return on equity for Techpoint, Inc. stands at 24.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 20.1%, showing how much profit it generates from its asset base. THPTF trades at a trailing price-to-earnings ratio of 42.57, above the Healthcare sector average of ~23x. Its free cash flow yield is 4.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 7.70 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 5.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Techpoint, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 44.04 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Techpoint, Inc. revenue of about $71.0M for fiscal 2026, with EPS near $1.08.
THPTF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that executives believe in the growth potential.
- Community sentiment has shifted positively, with discussions highlighting Techpoint's innovative product pipeline and its potential to capture market share.
- Analysts are optimistic about the company's strategic partnerships, which could enhance its competitive position in the tech landscape.
- Market perception is favorable, with growing interest in tech solutions that align with current digital transformation trends.
Bear Case
- Concerns about increasing competition in the tech sector have emerged, raising questions about Techpoint's ability to maintain its market position.
- Some community members express skepticism regarding the company's ability to scale its operations effectively in a rapidly evolving market.
- Recent news surrounding regulatory challenges in the tech industry has created uncertainty, impacting overall investor sentiment.
- There are mixed views on the sustainability of Techpoint's recent growth, with some analysts cautioning against potential overvaluation.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
THPTF Latest News
No recent news available for THPTF.
THPTF OTC Market Information
THPTF trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
THPTF Healthcare Stock FAQ
What happened to Techpoint, Inc. (THPTF) stock?
Techpoint, Inc. (THPTF) no longer trades on public markets. It was delisted in March 2026. The figures below are historical and are not a current quote.
Can I still buy THPTF shares?
No. THPTF stopped trading on public markets in March 2026, so the shares are not available through a broker. Anything you see quoted for THPTF elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before THPTF stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Techpoint, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does THPTF do?
Theratechnologies (THPTF) is a biopharmaceutical company focused on developing and commercializing therapies for unmet medical needs, particularly in metabolic disorders and infectious diseases. Their primary product is EGRIFTA SV (tesamorelin for injection), used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. The company operates primarily in North America and aims to expand its product pipeline through research and development efforts.
What do analysts say about THPTF stock?
Analyst coverage for Theratechnologies is limited, reflecting its smaller market capitalization and specialized focus. Key valuation metrics include revenue growth from EGRIFTA SV sales, R&D expenditure efficiency, and progress in clinical trials. Growth considerations center on expanding market penetration for EGRIFTA SV, potential label expansions, and advancement of its pipeline programs. Investors should monitor these factors to assess the company's growth potential and financial performance.
What are the main risks for THPTF?
The main risks for Theratechnologies include competition from alternative therapies, regulatory hurdles and pricing pressures, and reliance on a limited product portfolio centered around EGRIFTA SV. Patent expiration for EGRIFTA SV poses a long-term risk. Economic downturns affecting healthcare spending could also impact the company's revenue. Investors should carefully consider these risks when evaluating Theratechnologies as an investment.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for Theratechnologies.
- Information based on available company data and industry reports.